[{"NetIncomeLoss_1_Q2_USD":-42141000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"AccruedRoyaltiesCurrent_0_Q2_USD":2214000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":155951000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":156535000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":1100000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":79956000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":1011000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":2360000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1480000.0,"EquitySecuritiesFvNiCost_0_Q2_USD":346643000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":156473000.0,"Depreciation_2_Q2_USD":648000.0,"IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_2_Q2_USD":250000.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":4814000.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":1825000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":2210000.0,"AssetsCurrent_0_Q2_USD":735735000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":186317000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":84344000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":5698000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":2899000.0,"PaymentsToAcquireAvailableForSaleSecurities_2_Q2_USD":100813000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":19930000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":2735000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":261153000.0,"EquitySecuritiesFvNi_0_Q2_USD":348110000.0,"CommonStockSharesIssued_0_Q2_shares":157383379.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":1173000.0,"OperatingLeaseLiability_0_Q2_USD":8322000.0,"Assets_0_Q2_USD":759649000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-43000.0,"GainLossOnInvestments_2_Q2_USD":-1060000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":136931000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":64295000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":9829000.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":6240000.0,"PrepaidExpenseCurrent_0_Q2_USD":24846000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":11853000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-1060000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":437000.0,"AccountsReceivableNetCurrent_0_Q2_USD":43785000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":393000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":393000.0,"CommonStockValue_0_Q2_USD":15000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0_Q2_Security":1.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":1114000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":51155000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0_Q2_USD":1000.0,"CostsAndExpenses_2_Q2_USD":333696000.0,"CostsAndExpenses_1_Q2_USD":154113000.0,"IncreaseDecreaseInInventories_2_Q2_USD":20000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-128981000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-42186000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-756000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":739000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":400000.0,"OtherAssetsNoncurrent_0_Q2_USD":1731000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":310441000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":5669000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":2495804000.0,"Liabilities_0_Q2_USD":96636000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":1183000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":1390000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":1183000.0,"ShareBasedCompensation_2_Q2_USD":41855000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":1684000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1834286000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":121744000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":8004000.0,"CommonStockSharesOutstanding_0_Q2_shares":157383379.0,"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_2_Q2_USD":288000.0,"RestrictedCashNoncurrent_0_Q2_USD":5770000.0,"InvestmentsFairValueDisclosure_0_Q2_USD":631604000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_0_Q2_USD":4003000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_0_Q2_USD":4003000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-129771000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-41748000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-2000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-85885000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":2677000.0,"LiabilitiesCurrent_0_Q2_USD":86422000.0,"AccountsPayableCurrent_0_Q2_USD":6466000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":1000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":3234000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":1846000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.08,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-66000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_0_Q2_USD":1000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":316211000.0,"OperatingLeasePayments_2_Q2_USD":2582000.0,"OperatingLeasePayments_1_Q2_USD":1291000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":6687000.0,"NetIncomeLoss_2_Q2_USD":-130164000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-481000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-45000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":3867000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":4545000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":7880000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":51155000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"InterestReceivableCurrent_0_Q2_USD":2343000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":1507000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":1369000.0,"CommonStockSharesAuthorized_0_Q2_shares":225000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":200171000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":110103000.0,"OperatingIncomeLoss_2_Q2_USD":-133525000.0,"OperatingIncomeLoss_1_Q2_USD":-44010000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":348110000.0,"InventoryNet_0_Q2_USD":6210000.0,"PreferredStockValue_0_Q2_USD":null,"OperatingLeaseCost_2_Q2_USD":2915000.0,"OperatingLeaseCost_1_Q2_USD":1428000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":759649000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":20005000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":41855000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":19507000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2653000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":700000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":381000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q2_USD":105000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.83,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.27,"ProfitLoss_2_Q2_USD":-130164000.0,"StockholdersEquity_0_Q2_USD":663013000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":19611000.0,"Ticker":"ACAD","CIK":"1070494","name":"ACADIA PHARMACEUTICALS INC","OfficialName":"ACADIA Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3501345407.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]